Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15050865 | 1.00 | AOC3 (0.44) | AOC3IDO1TDO2SCN9AHTT | |
| SCHEMBL15050398 | 1.00 | AOC3 (0.44) | AOC3IDO1TDO2SCN9AHTT | |
| SCHEMBL15050395 | 1.00 | AOC3 (0.44) | AOC3IDO1TDO2SCN9AHTT | |
| SCHEMBL15050864 | 1.00 | AOC3 (0.44) | AOC3IDO1TDO2SCN9AHTT | |
| SCHEMBL15450371 | 0.85 | AOC3 (0.48) | AOC3IDO1TDO2HTTHDAC3 | |
| SCHEMBL14996734 | 0.85 | AOC3 (0.48) | AOC3IDO1TDO2HTTHDAC3 | |
| SCHEMBL3932318 | 0.85 | AOC3 (0.48) | AOC3IDO1TDO2HTTHDAC3 | |
| SCHEMBL14996733 | 0.85 | AOC3 (0.48) | AOC3IDO1TDO2HTTHDAC3 | |
| SCHEMBL11603843 | 0.84 | IDO1 (0.46) | AOC3IDO1TDO2HDAC3HDAC4 | |
| SCHEMBL31288604 | 0.83 | AOC3 (0.42) | AOC3IDO1TDO2HTTADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111057725-B | Use of ketoreductase for preparing (S) -1, 1-di (4-fluorophenyl) -2-propanol and preparation method thereof | 弈柯莱生物科技(上海)股份有限公司 | 2023-08-18 | — | — | CN | claimed |
| CN-111057725-A | Application of ketoreductase in preparation of (S) -1, 1-di (4-fluorophenyl) -2-propanol and preparation | 上海弈柯莱生物医药科技有限公司 | 2020-04-24 | — | — | CN | claimed |
| US-11931332-B2 | Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2024-03-19 | — | — | US | disclosed |
| CN-111057725-B | Use of ketoreductase for preparing (S) -1, 1-di (4-fluorophenyl) -2-propanol and preparation method thereof | 弈柯莱生物科技(上海)股份有限公司 | 2023-08-18 | — | — | CN | disclosed |
| CN-111057725-B | Use of ketoreductase for preparing (S) -1, 1-di (4-fluorophenyl) -2-propanol and preparation method thereof | 弈柯莱生物科技(上海)股份有限公司 | 2023-08-18 | — | — | CN | disclosed |
| EP-4204395-A1 | PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING NEURODEGENERATIVE DISEASE | Bio-Pharm Solutions Co., Ltd. (KR) | 2023-07-05 | — | — | EP | disclosed |
| EP-2968211-B1 | PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME | BIO PHARM SOLUTIONS CO LTD (KR) | 2021-05-12 | — | — | EP | disclosed |
| EP-2968211-B1 | PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME | BIO PHARM SOLUTIONS CO LTD (KR) | 2021-05-12 | — | — | EP | disclosed |
| CN-111057725-A | Application of ketoreductase in preparation of (S) -1, 1-di (4-fluorophenyl) -2-propanol and preparation | 上海弈柯莱生物医药科技有限公司 | 2020-04-24 | — | — | CN | disclosed |
| CN-111057725-A | Application of ketoreductase in preparation of (S) -1, 1-di (4-fluorophenyl) -2-propanol and preparation | 上海弈柯莱生物医药科技有限公司 | 2020-04-24 | — | — | CN | disclosed |
| EP-2797881-B1 | PHENYL ALKYL CARBAMATE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | BIO PHARM SOLUTIONS CO LTD (KR) | 2018-11-14 | — | — | EP | disclosed |
| US-9504668-B2 | Phenyl alkyl carbamate compounds for use in preventing or treating epilepsy or epilepsy-related syndrome | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2016-11-29 | — | — | US | disclosed |
| US-20160023999-A1 | PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2016-01-28 | — | — | US | disclosed |
| EP-2968211-A1 | PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME | Bio-Pharm Solutions Co., Ltd. (KR) | 2016-01-20 | — | — | EP | disclosed |
| US-9029589-B2 | Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2015-05-12 | — | — | US | disclosed |
| EP-2797881-A1 | Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same | Bio-Pharm Solutions Co., Ltd. (KR) | 2014-11-05 | — | — | EP | disclosed |
| WO-2014142519-A1 | PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2014-09-18 | — | — | WO | disclosed |
| WO-2013100566-A1 | Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2013-07-04 | — | — | WO | disclosed |
| US-20130165509-A1 | PHENYL ALKYL CARBAMATE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165509-A1 | PHENYL ALKYL CARBAMATE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | MYLK, PDE3A, TNNC1 | AOC3 3584/4885IDO1 2931/4885TDO2 4331/4885 |
| US-11931332-B2 | Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease | SNCA, MAPT, CHAT | AOC3 811/4885IDO1 2514/4885TDO2 4473/4885 |
| US-20160023999-A1 | PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME | SCN1A, GABARAPL1, NAA10 | AOC3 2921/4885IDO1 2990/4885TDO2 4523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.